419 related articles for article (PubMed ID: 15839836)
1. Carbohydrate-remodelled acid alpha-glucosidase with higher affinity for the cation-independent mannose 6-phosphate receptor demonstrates improved delivery to muscles of Pompe mice.
Zhu Y; Li X; McVie-Wylie A; Jiang C; Thurberg BL; Raben N; Mattaliano RJ; Cheng SH
Biochem J; 2005 Aug; 389(Pt 3):619-28. PubMed ID: 15839836
[TBL] [Abstract][Full Text] [Related]
2. Conjugation of mannose 6-phosphate-containing oligosaccharides to acid alpha-glucosidase improves the clearance of glycogen in pompe mice.
Zhu Y; Li X; Kyazike J; Zhou Q; Thurberg BL; Raben N; Mattaliano RJ; Cheng SH
J Biol Chem; 2004 Nov; 279(48):50336-41. PubMed ID: 15383547
[TBL] [Abstract][Full Text] [Related]
3. Glycoengineered acid alpha-glucosidase with improved efficacy at correcting the metabolic aberrations and motor function deficits in a mouse model of Pompe disease.
Zhu Y; Jiang JL; Gumlaw NK; Zhang J; Bercury SD; Ziegler RJ; Lee K; Kudo M; Canfield WM; Edmunds T; Jiang C; Mattaliano RJ; Cheng SH
Mol Ther; 2009 Jun; 17(6):954-63. PubMed ID: 19277015
[TBL] [Abstract][Full Text] [Related]
4. Reveglucosidase alfa (BMN 701), an IGF2-Tagged rhAcid α-Glucosidase, Improves Respiratory Functional Parameters in a Murine Model of Pompe Disease.
Peng J; Dalton J; Butt M; Tracy K; Kennedy D; Haroldsen P; Cahayag R; Zoog S; O'Neill CA; Tsuruda LS
J Pharmacol Exp Ther; 2017 Feb; 360(2):313-323. PubMed ID: 27856936
[TBL] [Abstract][Full Text] [Related]
5. Efficient therapy for refractory Pompe disease by mannose 6-phosphate analogue grafting on acid α-glucosidase.
Basile I; Da Silva A; El Cheikh K; Godefroy A; Daurat M; Harmois A; Perez M; Caillaud C; Charbonné HV; Pau B; Gary-Bobo M; Morère A; Garcia M; Maynadier M
J Control Release; 2018 Jan; 269():15-23. PubMed ID: 29108866
[TBL] [Abstract][Full Text] [Related]
6. Recombinant human acid alpha-glucosidase corrects acid alpha-glucosidase-deficient human fibroblasts, quail fibroblasts, and quail myoblasts.
Yang HW; Kikuchi T; Hagiwara Y; Mizutani M; Chen YT; Van Hove JL
Pediatr Res; 1998 Mar; 43(3):374-80. PubMed ID: 9505277
[TBL] [Abstract][Full Text] [Related]
7. Glycosylation-independent lysosomal targeting of acid α-glucosidase enhances muscle glycogen clearance in pompe mice.
Maga JA; Zhou J; Kambampati R; Peng S; Wang X; Bohnsack RN; Thomm A; Golata S; Tom P; Dahms NM; Byrne BJ; LeBowitz JH
J Biol Chem; 2013 Jan; 288(3):1428-38. PubMed ID: 23188827
[TBL] [Abstract][Full Text] [Related]
8. Hyaluronidase increases the biodistribution of acid alpha-1,4 glucosidase in the muscle of Pompe disease mice: an approach to enhance the efficacy of enzyme replacement therapy.
Matalon R; Surendran S; Campbell GA; Michals-Matalon K; Tyring SK; Grady J; Cheng S; Kaye E
Biochem Biophys Res Commun; 2006 Nov; 350(3):783-7. PubMed ID: 17027913
[TBL] [Abstract][Full Text] [Related]
9. Correction of glycogen storage disease type II by enzyme replacement with a recombinant human acid maltase produced by over-expression in a CHO-DHFR(neg) cell line.
Martiniuk F; Chen A; Donnabella V; Arvanitopoulos E; Slonim AE; Raben N; Plotz P; Rom WN
Biochem Biophys Res Commun; 2000 Oct; 276(3):917-23. PubMed ID: 11027569
[TBL] [Abstract][Full Text] [Related]
10. Replacing acid alpha-glucosidase in Pompe disease: recombinant and transgenic enzymes are equipotent, but neither completely clears glycogen from type II muscle fibers.
Raben N; Fukuda T; Gilbert AL; de Jong D; Thurberg BL; Mattaliano RJ; Meikle P; Hopwood JJ; Nagashima K; Nagaraju K; Plotz PH
Mol Ther; 2005 Jan; 11(1):48-56. PubMed ID: 15585405
[TBL] [Abstract][Full Text] [Related]
11. Antibody-mediated enzyme replacement therapy targeting both lysosomal and cytoplasmic glycogen in Pompe disease.
Yi H; Sun T; Armstrong D; Borneman S; Yang C; Austin S; Kishnani PS; Sun B
J Mol Med (Berl); 2017 May; 95(5):513-521. PubMed ID: 28154884
[TBL] [Abstract][Full Text] [Related]
12. Adjunctive β2-agonist treatment reduces glycogen independently of receptor-mediated acid α-glucosidase uptake in the limb muscles of mice with Pompe disease.
Farah BL; Madden L; Li S; Nance S; Bird A; Bursac N; Yen PM; Young SP; Koeberl DD
FASEB J; 2014 May; 28(5):2272-80. PubMed ID: 24448824
[TBL] [Abstract][Full Text] [Related]
13. Enhanced efficacy of enzyme replacement therapy in Pompe disease through mannose-6-phosphate receptor expression in skeletal muscle.
Koeberl DD; Luo X; Sun B; McVie-Wylie A; Dai J; Li S; Banugaria SG; Chen YT; Bali DS
Mol Genet Metab; 2011 Jun; 103(2):107-12. PubMed ID: 21397538
[TBL] [Abstract][Full Text] [Related]
14. Complete correction of acid alpha-glucosidase deficiency in Pompe disease fibroblasts in vitro, and lysosomally targeted expression in neonatal rat cardiac and skeletal muscle.
Pauly DF; Johns DC; Matelis LA; Lawrence JH; Byrne BJ; Kessler PD
Gene Ther; 1998 Apr; 5(4):473-80. PubMed ID: 9614571
[TBL] [Abstract][Full Text] [Related]
15. Biochemical and pharmacological characterization of different recombinant acid alpha-glucosidase preparations evaluated for the treatment of Pompe disease.
McVie-Wylie AJ; Lee KL; Qiu H; Jin X; Do H; Gotschall R; Thurberg BL; Rogers C; Raben N; O'Callaghan M; Canfield W; Andrews L; McPherson JM; Mattaliano RJ
Mol Genet Metab; 2008 Aug; 94(4):448-455. PubMed ID: 18538603
[TBL] [Abstract][Full Text] [Related]
16. Species-specific differences in the processing of acid α-glucosidase are due to the amino acid identity at position 201.
Moreland RJ; Higgins S; Zhou A; VanStraten P; Cauthron RD; Brem M; McLarty BJ; Kudo M; Canfield WM
Gene; 2012 Jan; 491(1):25-30. PubMed ID: 21963446
[TBL] [Abstract][Full Text] [Related]
17. Glycogen storage in multiple muscles of old GSD-II mice can be rapidly cleared after a single intravenous injection with a modified adenoviral vector expressing hGAA.
Xu F; Ding E; Migone F; Serra D; Schneider A; Chen YT; Amalfitano A
J Gene Med; 2005 Feb; 7(2):171-8. PubMed ID: 15515143
[TBL] [Abstract][Full Text] [Related]
18. Differential muscular glycogen clearance after enzyme replacement therapy in a mouse model of Pompe disease.
Hawes ML; Kennedy W; O'Callaghan MW; Thurberg BL
Mol Genet Metab; 2007 Aug; 91(4):343-51. PubMed ID: 17572127
[TBL] [Abstract][Full Text] [Related]
19. Four unreported types of glycans containing mannose-6-phosphate are heterogeneously attached at three sites (including newly found Asn 233) to recombinant human acid alpha-glucosidase that is the only approved treatment for Pompe disease.
Park H; Kim J; Lee YK; Kim W; You SK; Do J; Jang Y; Oh DB; Il Kim J; Kim HH
Biochem Biophys Res Commun; 2018 Jan; 495(4):2418-2424. PubMed ID: 29274340
[TBL] [Abstract][Full Text] [Related]
20. Salmeterol enhances the cardiac response to gene therapy in Pompe disease.
Han SO; Li S; Koeberl DD
Mol Genet Metab; 2016 May; 118(1):35-40. PubMed ID: 27017193
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]